Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a ...

Novo Nordisk A/S (NYSE: NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a multiyear anticompetitive scheme designed to delay generic competition. • What’s ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Prompt injection attacks can manipulate AI behavior in ways that traditional cybersecurity ...

Under its former childhood vaccine schedule, the U.S. Centers for Disease Control and Prevention recommended that kids get 12 different vaccines protecting against 16 diseases before age 10. It didn’t ...

GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients ...

KAIST researchers have developed a way to reprogram immune cells already inside tumors into cancer-killing machines. A drug injected directly into the tumor is absorbed by macrophages, prompting them ...

Mounjaro (tirzepatide) is prescribed to manage blood sugar levels in people with type 2 diabetes. It’s available as a single-dose prefilled pen. You will administer your Mounjaro injections into your ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min One of Cincinnati's best-funded ...

OpenAI’s secret hardware project with Apple design legend Jony Ive could be an AI-powered pen that’s basically ChatGPT in your hand, according to a newly surfaced patent. The smart pen packs a camera ...

Electronic fuel injection revolutionized the auto industry in the 1980s. It came to replace the carburetor in the task of sending fuel to the engine's cylinders but it does much more: it controls ...

The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for patients with a ...